Tocilizumab shortage: Supply improving

TGA

Roche Products Pty Limited (Roche Australia) have advised that availability of tocilizumab (Actemra) in Australia is improving but supply disruptions to some tocilizumab products will continue beyond January 2022.

Information for IV tocilizumab (Actemra) patients

A small amount of 400mg IV tocilizumab is arriving in Australia in late December. Following supply modelling and collaboration between the TGA, Roche Australia, the Australian Rheumatology Association and Arthritis Australia, it has been advised that the use of IV tocilizumab (Actemra) in some patient groups can be increased.

Please refer to the Australian Rheumatology Association clinical guidance web statement

/Public Release. View in full here.